What is CRISPR Gene Editing Technology

CRISPR (short for “clustered regularly interspaced short palindromic repeats”) is a technology that research scientists use to selectively modify the DNA of living organisms.

CRISPR (short for "clustered regularly interspaced short palindromic repeats") is a natural defense mechanism found in bacteria that helps them fight off viruses.

The CRISPR gene-editing system has two components. The first is one of the bacterial DNA-cutting Cas enzymes, Cas9, and the second is a targeting device—also called a guide—made of RNA. The sequence of the guide RNA is complementary to the DNA sequence that the researcher wants to target.

Numerous studies have further refined the system and expanded its applications. For example, Mali et al. demonstrated the successful use of CRISPR-Cas9 to edit the genomes of human cells, highlighting its potential for biomedical research [14]. The specificity of CRISPR-Cas9 technology has been a topic of great interest and improvement. Studies have explored strategies to reduce off-target effects and enhance precision.

This technology possesses excellent features for manipulating genomes, such as easy design, low costs, rapid turnaround time, and particularly its high accuracy and efficiency. Hence, CRISPR-Cas systems have multiple advantages and have overtaken the earlier-used gene-editing tools [e.g. ...

Other variations of Cas9, such as catalytically inactive endonuclease dead Cas9 (dCas9) in which the nuclease domains are deactivated, may provide therapeutic utility while mitigating the risks of DSBs (73). dCas9 can transiently manipulate expression of specific genes without introducing DSBs through fusion of transcriptional activating or repressing domains or proteins to the DNA-binding effector (74). Other variants such as Cas9n can also be considered, which induces SSBs rather than DSBs. Further modifications of these Cas9 variants has led to the development of base editors and prime editors, a key innovation for safe therapeutic application of CRISPR technology (see Precision Gene Editing With CRISPR section).

Nature - The safety and efficacy of genome editing in human embryos hasn’t been proven, researchers warn.

Together, this study showed that using ex vivo CRISPR-edited, PD-1-ablated, patient-derived T cells for cancer treatment is clinically feasible and generally safe. This finding echoes the conclusions of two other recent clinical studies that ...

These concerns should not undermine the value of the technology itself but instead warrant parallel technological advancement to mitigate the concerns while employing its beneficial potentials. Figure 3 Paths of Gene Drives in Populations. There are multiple paths that CRISPR gene drives can take, but safety concerns are foreseeable on any of these paths.